Michael Vaslamatzis

Tumor to Tumor Metastasis

Constantina Petraki, Michael Vaslamatzis, Theodoros Argyrakos et al. · International Journal of Surgical Pathology · 2003 · 121 citations

Tumor Biology, Surgical Oncology, Urology +12

Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours

C.G. Alexopoulos, Michael Vaslamatzis, G Hatzidimitriou · British Journal of Cancer · 1999 · 99 citations · Full text

Immunology, Hepatitis B, Pathology +16

Changes in serum lipids and lipoproteins in cancer patients during chemotherapy

C.G. Alexopoulos, Stavros Pournaras, Michael Vaslamatzis et al. · Cancer Chemotherapy and Pharmacology · 1992 · 68 citations

Lipid Analysis, Oncology, Medicine +8

Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project

John Souglakos, Ioannis Boukovinas, Stylianos Kakolyris et al. · Annals of Oncology · 2019 · 46 citations · Full text

High-risk Stage Ii, Oncology, Gastrointestinal Oncology +9

Prognostic Implications of the Immunohistochemical Expression of Human Kallikreins 5, 6, 10 and 11 in Renal Cell Carcinoma

Constantina Petraki, Alkiviadis Gregorakis, Michael Vaslamatzis et al. · Tumor Biology · 2005 · 41 citations